Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? - Wikidata - wikimedia - TriplyDB

Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?

Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?

http://www.wikidata.org/entity/Q37787320

about

Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Pharmacological management of diabetic dyslipidemia.Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.Gallic Acid Improves Health-Associated Biochemical Parameters and Prevents Oxidative Damage of DNA in Type 2 Diabetes Patients: Results of a Placebo-Controlled Pilot Study.

P2860

Q24608214-187EE3B4-C84E-482F-B262-19CCF3162282 Q36432198-687BF814-CF64-45E3-840B-3C0DEFFD0D06 Q38231113-F301573C-228E-4015-A9CD-E3489D87831D Q38299279-07C95F94-B0D0-4D01-857E-7ABE86E61AAF Q38460480-58C81101-DF9D-4573-9659-48F1E15C8882 Q39015072-EDA87FD6-9AB5-4E56-BD2D-AF082A026BC5 Q47154672-42D3C379-C1ED-4255-B5C5-2773146A8AB9 Q47330451-9B0B8D85-37C6-44C5-A9EA-9C3DF593726C Q49377852-2E2F6734-E50A-488E-9AD9-8D7C20146ABE

P2860

Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?

http://www.wikidata.org/entity/Q37787320

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Should we measure routinely ox ...... subjects with type 2 diabetes?

@en

Should we measure routinely ox ...... subjects with type 2 diabetes?

@nl

type

label

Should we measure routinely ox ...... subjects with type 2 diabetes?

@en

Should we measure routinely ox ...... subjects with type 2 diabetes?

@nl

prefLabel

Should we measure routinely ox ...... subjects with type 2 diabetes?

@en

Should we measure routinely ox ...... subjects with type 2 diabetes?

@nl

P1433

Q37787320-F57E01C7-8DC8-4F07-AE97-27E73DD7B2BB

P1476

Q37787320-A98263D5-A6A9-448E-8B1A-C316FFAC8DBA

P2093

Q37787320-043C8538-80C0-41EC-BC9B-EAA6F82B085B

Q37787320-5DE3B5D2-2C0B-4C05-9084-0F8B9547789E

Q37787320-6A83C571-D0C8-4EB8-953B-DC65187EB70D

Q37787320-A6F7BB8F-99FD-4A7F-A51E-11A0B4CA0471

Q37787320-DE6E3634-AFFA-4F40-AD0D-705FEACE1189

P2860

Q37787320-0980184A-14D6-40D4-81A1-2F15F34A777A

Q37787320-0FB22988-73DD-427C-8F5E-25788E871476

Q37787320-1AB00F6A-6BA8-4ECB-9FDA-64FEEE35F284

Q37787320-364BFA67-F74F-4137-8C6D-3907E7D9CB14

Q37787320-536B1366-3C25-4661-AFCB-E43B75D2AC2F

Q37787320-7BCA0522-F89F-4992-B624-227D47110067

Q37787320-C26FFFF1-E4D3-4F2B-AF95-66B06727E022

Q37787320-CDF1D157-C0A1-4776-946E-68A81A02CB2C

Q37787320-D4DE8261-C809-4263-BF84-EFDAB2F9EA62

Q37787320-DDD473C7-BEBE-4741-859F-B303F5DEAA3B

P304

Q37787320-5CC1A7E3-5559-45FA-83B8-7FBA566351E3

P31

Q37787320-D48D20C1-12C7-41EA-B297-EDC2186F7450

P356

Q37787320-EA55E91E-DD80-4898-95B7-9721CB25102E

P433

Q37787320-8CCBC6BE-3F85-4091-B117-A538C83BD35B

P478

Q37787320-B6793DF2-9AF5-48D9-B5B5-9284122B61FD

P50

Q37787320-9ADBDBC8-8DA7-4D21-8663-285E6A4A4C67

Q37787320-AE018E59-EF2E-4D5B-9C02-F70852AD9F86

P577

Q37787320-DBBC1AFF-2925-49E5-A101-29C6B143D75E

P5875

Q37787320-C08DC4F0-B05C-464F-A22A-57F3C4DC5571

P698

Q37787320-7A41CC60-B860-4049-BA51-7E3F8EB4802E

P921

Q37787320-5C68AE4E-A89A-4874-9BB0-4EE83C27324F

Q37787320-A85650E8-F7B9-44D6-8FE0-37F587F0F747

Q37787320-FB7E5AD4-848D-472A-BA0A-7BDEC6D82984

P356

J.1742-1241.2010.02378.X

P1433

International Journal of Clinical Practice

P1476

Should we measure routinely ox ...... subjects with type 2 diabetes?

@en

P2093

D Sakellariou

http://www.w3.org/2001/XMLSchema#string

G B Rini

http://www.w3.org/2001/XMLSchema#string

K Berneis

http://www.w3.org/2001/XMLSchema#string

S Koulouris

http://www.w3.org/2001/XMLSchema#string

S Pastromas

http://www.w3.org/2001/XMLSchema#string

P2860

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993.

Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women.

Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts.

In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression.

Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.

Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.

LDL subclass phenotypes and the insulin resistance syndrome in women.

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

P304

1632-1642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1742-1241.2010.02378.X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Antonis S. Manolis

P577

2010-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46218234

http://www.w3.org/2001/XMLSchema#string

P698

20831734

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

type-2 diabetes